行情

PSTI

PSTI

Pluristem
NASDAQ

实时行情|Nasdaq Last Sale

3.740
-0.040
-1.07%
交易中 14:07 01/29 EST
开盘
3.760
昨收
3.780
最高
3.807
最低
3.702
成交量
1.51万
成交额
--
52周最高
11.80
52周最低
3.110
市值
5,875.65万
市盈率(TTM)
-1.4372
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PSTI 新闻

  • Does The Pluristem Therapeutics Inc. (NASDAQ:PSTI) Share Price Fall With The Market?
  • Simply Wall St..01/09 16:53
  • Pluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study
  • GlobeNewswire.2019/12/17 12:00
  • Benzinga's Top Upgrades, Downgrades For December 16, 2019
  • Benzinga.2019/12/16 15:10
  • Goldman likes Amgen and UnitedHealth Group in premarket analyst action
  • Seeking Alpha - Article.2019/12/16 13:14

更多

所属板块

生物技术和医学研究
-0.03%
制药与医学研究
+0.43%

热门股票

名称
价格
涨跌幅

PSTI 简况

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
展开

Webull提供Pluristem Therapeutics Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。